Across TCGA pan-cancer cohorts, IGLV5-45 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGLV5-45 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher IGLV5-45 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV5-45 expression acts as an unfavorable survival marker.
LUSC are the cancer types where IGLV5-45 Mutation most reproducibly stratifies survival.